Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Reduction (functional) | = 5 % | The compound was tested for percent reduction in plasma glucose after 6 days of treatment at a dose of 100 mg/kg/day (oral gavage) in mice | ChEMBL. | 10464013 |
Reduction (functional) | = 5 % | The compound was tested for percent reduction in plasma glucose after 6 days of treatment at a dose of 100 mg/kg/day (oral gavage) in mice | ChEMBL. | 10464013 |
Reduction (functional) | = 24 % | The compound was tested for percent reduction in plasma triglyceride after 6 days of treatment at 100 mg/kg/day in mice | ChEMBL. | 10464013 |
Reduction (functional) | = 24 % | The compound was tested for percent reduction in plasma triglyceride after 6 days of treatment at 100 mg/kg/day in mice | ChEMBL. | 10464013 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.